Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest PROLOR Biotech Inc. Stories

2013-08-29 12:26:13

MIAMI and NES-ZIONA, Israel, Aug. 29, 2013 /PRNewswire/ -- OPKO Health, Inc. (NYSE: OPK) ("OPKO") and PROLOR Biotech, Inc. (NYSE MKT: PBTH) ("PROLOR") jointly announced today the completion of the acquisition of PROLOR by OPKO. Pursuant to the acquisition, stockholders of PROLOR will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. "We are pleased to complete the acquisition of PROLOR and broaden our portfolio of market-transforming therapies in...

2013-07-03 08:24:34

--New Data Show a Simple Subcutaneous Injection of Factor VIIa-CTP Could Potentially Replace Current Therapies Administered Via Infusion-- AMSTERDAM and NES-ZIONA, Israel, July 3, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new results from preclinical studies of its long-acting clotting factor VIIa (Factor VIIa-CTP), a next-generation investigational therapy in advanced preclinical development for the potential treatment...

2013-06-13 08:27:32

-- hGH-CTP and MOD-6030 to be Featured in Oral and Poster Presentations at Endocrine Society's Annual Meeting -- SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of...

2013-06-04 08:28:40

NES-ZIONA, Israel, June 4, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Mkt: PBTH), a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone (hGH), in growth hormone deficient adults. PROLOR is developing hGH-CTP to provide growth hormone deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly...

2013-05-31 08:24:26

NES-ZIONA, Israel, May 31, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Jefferies 2013 Global Healthcare Conference, being held at the Grand Hyatt Hotel in New York City. The presentation is scheduled for June 4, 2013 at 4:30 pm ET. A live webcast of the company's presentation will be available at the Investors...

2013-04-29 12:29:18

NEW YORK, April 29, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of PROLOR Biotech, Inc. ("PROLOR" or the "Company") (NYSE MKT: PBTH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to OPKO Health, Inc. ("OPKO") (NYSE: OPK). (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) Click here to learn more about the investigation http://zlk.9nl.com/prolor-biotech-pbth/,...

2013-04-25 20:22:43

BALA CYNWYD, Pa., April 25, 2013 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of PROLOR Biotech, Inc. ("PROLOR" or the "Company") (NYSE- PBTH) relating to the proposed acquisition by OPKO Health, Inc. ("OPKO"). Under the terms of the transaction, PROLOR shareholders will receive only 0.9951 shares of OPKO stock for each share of PROLOR stock they own. The transaction values PROLOR stock at...

2013-04-24 20:23:24

SAN DIEGO, Calif. and NES-ZIONA, Israel, April 24, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of PROLOR Biotech, Inc. (NYSE MKT: PBTH) by OPKO Health, Inc. (NYSE: OPK). On April 24, 2013, PROLOR and OPKO announced the signing of a definitive merger agreement whereby PROLOR shareholders will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock owned, a value of approximately $7.00 per PROLOR share. The...

2013-04-24 04:21:43

--Acquisition Adds Promising Late Stage Product hGH-CTP Targeting Growth Hormone Deficiency and Preclinical Products Targeting Hemophilia, Obesity & Diabetes-- MIAMI and NES-ZIONA, Israel, April 24, 2013 /PRNewswire/ -- OPKO Health, Inc. (NYSE: OPK) and PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing...

2013-03-05 08:28:37

NES-ZIONA, Israel, March 5, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent application covering the company's long-acting CTP-enhanced human growth hormone (hGH-CTP). Upon issuance, the new patent will provide PROLOR with additional intellectual property protection that covers methods for decreasing body fat in humans through the use of hGH-CTP therapy....